Longeveron Inc., a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
IPO Year: 2021
Exchange: NASDAQ
Website: longeveron.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/6/2024 | $10.00 | Buy | ROTH MKM |
| 1/5/2022 | $20.00 | Buy | EF Hutton |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
ROTH MKM initiated coverage of Longeveron with a rating of Buy and set a new price target of $10.00
EF Hutton initiated coverage of Longeveron with a rating of Buy and set a new price target of $20.00
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
Fastest customizable press release news feed in the world
Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS II top-line trial results are anticipated in the third quarter of 2026, after the final follow-up at 12-monthsLaromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in late 2026, if ELPIS II results are positiveStem cell therapy pipeline expanded with FDA approval of IND application for laromestrocel as a potential treatment for Pediatric Dilated CardiomyopathyCompany to host conference call and webcast today at 4:30 p.m. ET MIAMI, Au
MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced the closing of its previously announced public offering of 5,882,354 of the Company's Class A common stock (or pre-funded warrants in lieu thereof), together with short-term warrants to purchase up to 14,705,885 shares of Class A common stock at a combined public offering price of $0.85 per share of Class A common stock (or pre-funded warrant in lieu thereof) and accompanying short-term warrants. The short-term w
MIAMI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced the pricing of a public offering of 5,882,354 of the Company's Class A common stock (or pre-funded warrants in lieu thereof), together with short-term warrants to purchase up to 14,705,885 shares of Class A common stock at a combined public offering price of $0.85 per share of Class A common stock (or pre-funded warrant in lieu thereof) and accompanying short-term warrants. The short-term warrants will have an ex
MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report second quarter 2025 financial results and provide a business update on Wednesday, August 13, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details: Conference Call Number:1.877.407.0789Conference ID:13754295 Call meTM Feature:Click HereWebcast:Click Here An archived replay of the webcast will be available on t
Longeveron has licensed issued US Patent 12,168,028 B2, entitled "Methods for obtaining cardiomyogenic precursor cells" from the University of MiamiNew patent protects a method to derive GHRH-Receptor+ cardiomyogenic cells from pluripotent stem cells (PSCs)New technology substantially advances Longeveron's repertoire of stem cell therapy technologiesOpportunity to expand pipeline in cardiovascular, rare and pediatric disease areas MIAMI, July 21, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric, and chronic aging-related conditions, today announced that i
Accepted IND application allows for development program to move directly to a Phase 2 pivotal registration clinical trialPhase 2 clinical trial initiation anticipated in first half of 2026Pediatric cardiomyopathies affect at least 100,000 children worldwideEffective treatment options are limited, with nearly 40% of children with DCM requiring a heart transplant or dying within two years of diagnosis MIAMI, July 08, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that the U.S. Food and Drug Administration (FDA) has ap
Mr. Powell to oversee Longeveron's partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Than Powell as Chief Business Officer, effective July 7, 2025. In this role, he will lead the Company's overall business strategy, Alzheimer's disease program partnering efforts, and international strategy for the hypoplastic left heart syndrome (HLHS) program. "We are delighted to have Than join Longeveron at this transformational time in the Company's
Top-line trial results are anticipated in the third quarter of 2026, after the final follow-up at 12-monthsLaromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in 2026, if ELPIS II results are positiveU.S. FDA has awarded laromestrocel HLHS program Rare Pediatric Disease designation, Orphan drug designation, and Fast track designationLaromestrocel HLHS program addresses unmet medical needs with U.S. market potential of up to $1 billion MIAMI, June 24, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic a
MIAMI, June 09, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Wa'el Hashad, CEO, will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, taking place June 16-17, 2025. Details for the Company's corporate presentation: Pre-recorded presentation available on-demand Monday, June 16, at 7:00 a.m. ETLongeveron presentation webcast link: Click Here The webcast for this conference presentation may be accessed at the "Events and Presentations" section of the Company's website. A replay of
Focus on potential partnership and strategic opportunities for the Company's stem cell therapy program for Alzheimer's diseaseRecent Type B meeting with FDA provided alignment on a planned single, pivotal Phase 2/3 clinical trial, which if positive, would be acceptable for Biological License Application (BLA) submission for Alzheimer's diseaseInitiation of planned single, pivotal Phase 2/3 clinical trial in mild Alzheimer's disease anticipated in 2H 2026, contingent upon obtaining non-dilutive funding and/or partnering supportResults from the Phase 2a clinical trial (CLEAR MIND) evaluating laromestrocel as a potential treatment for Alzheimer's disease were published in the peer reviewed jour
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
SCHEDULE 13G - Longeveron Inc. (0001721484) (Subject)
8-K - Longeveron Inc. (0001721484) (Filer)
10-Q - Longeveron Inc. (0001721484) (Filer)
8-K - Longeveron Inc. (0001721484) (Filer)
424B4 - Longeveron Inc. (0001721484) (Filer)
EFFECT - Longeveron Inc. (0001721484) (Filer)
S-1/A - Longeveron Inc. (0001721484) (Filer)
S-1 - Longeveron Inc. (0001721484) (Filer)
8-K - Longeveron Inc. (0001721484) (Filer)
S-8 - Longeveron Inc. (0001721484) (Filer)
Live Leadership Updates
Mr. Powell to oversee Longeveron's partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Than Powell as Chief Business Officer, effective July 7, 2025. In this role, he will lead the Company's overall business strategy, Alzheimer's disease program partnering efforts, and international strategy for the hypoplastic left heart syndrome (HLHS) program. "We are delighted to have Than join Longeveron at this transformational time in the Company's
MIAMI, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Devin Blass as Chief Technology Officer (CTO) and Senior Vice President of Chemistry, Manufacturing, and Controls (CMC), effective December 2, 2024. In this role, he will lead the Company's technological and manufacturing strategies. "We are delighted to have Devin join Longeveron at this transformational time in the Company's evolution," said Wa'el Hashad, Chief Executive Officer at Longeveron. "This appointment reinforces Longevero
MIAMI, July 09, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, including hypoplastic left heart syndrome (HLHS) and Alzheimer's disease, today announced that Neha Motwani, a senior healthcare investment banker, has been elected to the Longeveron Board of Directors at the Company's recent Annual Meeting of Stockholders. "I am delighted to welcome Neha, with her tremendous healthcare industry experience, to the Board of Directors," said Joshua Hare, Co-founder, Chief Science Officer and Chairman of the Board at Longeveron. "Her exte
MIAMI, July 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Roger Hajjar, MD, Director of the Gene and Cell Therapy Institute at Mass General Brigham, has been elected to the Longeveron Board of Directors. Dr. Hajjar is an internationally recognized scientist whose cardiac gene therapy discoveries have spurred clinical trials for heart failure, whose methodologies for cardiac-directed gene transfer are currently utilized by investigators around the world, and who was appointed as the inaugural director of the
Richard Kender, retired SVP of Business Development and Corporate Licensing for Merck & Co., Inc., has been appointed to the Longeveron BoardDr. Roger Hajjar, former head of R&D at Ring Therapeutics, has been nominated as a candidate for the Board, subject to election at the Company's Annual Meeting of StockholdersNeha Motwani, former managing director and senior healthcare investment banker at William Blair, Truist, and Oppenheimer and Company, also has been nominated as a candidate for the Board, subject to election at the Company's Annual Meeting of StockholdersExisting directors, Dr. Joshua Hare and Ursula Ungaro, have been nominated as candidates for re-election to the Board, subject to
MIAMI, July 20, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today the appointment of Lisa Locklear as Executive Vice President and Chief Financial Officer. Ms. Locklear is an accomplished leader with global business experience, and is a respected finance professional in the biopharmaceutical industry. The appointment is effective as of July 31, 2023. "Lisa brings to Longeveron keen strategic perspective and expansive industry knowledge, and her financial leadership ability will be vital as we continue advancing ou
MIAMI, July 11, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today the appointment of Nataliya Agafonova, M. D., as the Company's Chief Medical Officer (CMO), effective as of July 1, 2023. As CMO, Dr. Agafonova will lead Longeveron's global clinical development and regulatory strategy for the Company's investigational products. "Dr. Agafonova brings deep pharmaceutical industry experience and an extensive background in successful drug development, and we are delighted to welcome her to the Longeveron leadership tea
Hashad is a former executive at Avanir, Amgen, Boehringer Ingelheim, Eli Lilly, and early-stage biotechnology companies Global leader brings over 35 years of experience with focus on drug approval and commercialization, mergers and acquisitions, and business development MIAMI, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for rare pediatric disease, aging-related conditions, and unmet medical needs, today announced the appointment of seasoned global pharmaceutical leader Wa'el Hashad as Chief Executive Officer. Mr. Hashad will assume the role of Chief Executive Officer
-Geoff Green stepping down as CEO, effective June 1, 2022 -K. Chris Min, M.D., Ph.D., current Chief Medical Officer, appointed Interim CEO -Nationwide search is underway for permanent CEO MIAMI, May 09, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company") announced today the resignation of Chief Executive Officer (CEO) Geoff Green, who is leaving the Company effective June 1st, 2022, to pursue new opportunities. Longeveron's Board of Directors has approved the appointment of current Chief Medical Officer, K. Chris Min, M.D., Ph.D., as Interim CEO, to succeed Mr. Green. The Board has formed a search committee and retained an executive search firm to assist i
MIAMI, April 05, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and other specific life-threatening conditions, announced today the addition of K. Chris Min, M.D., Ph.D. to the Longeveron executive leadership team in the role of Chief Medical Officer (CMO), effective April 4, 2022. Dr. Min will lead global clinical development and regulatory strategy for Longeveron's investigational products, with advancing its lead product Lomecel-B into pivotal stage trials and approval as his top priority. "We are very pleased to welcome Chris to the Longeveron team," sai
This live feed shows all institutional transactions in real time.
SC 13G/A - Longeveron Inc. (0001721484) (Subject)
SC 13G - Longeveron Inc. (0001721484) (Subject)
SC 13G - Longeveron Inc. (0001721484) (Subject)
SC 13D/A - Longeveron Inc. (0001721484) (Subject)
SC 13G - Longeveron Inc. (0001721484) (Subject)
SC 13D/A - Longeveron Inc. (0001721484) (Subject)
SC 13D/A - Longeveron Inc. (0001721484) (Subject)
SC 13D/A - Longeveron Inc. (0001721484) (Subject)
Live finance-specific insights
MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report second quarter 2025 financial results and provide a business update on Wednesday, August 13, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details: Conference Call Number:1.877.407.0789Conference ID:13754295 Call meTM Feature:Click HereWebcast:Click Here An archived replay of the webcast will be available on t
Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to complete enrollment in the second quarter of 2025Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in 2026, if ELPIS II is successfulResults from the Phase 2a clinical trial (CLEAR MIND) evaluating laromestrocel as a potential treatment for Alzheimer's disease were published in Nature MedicinePositive FDA meeting regarding development pathway for laromestrocel in mild Alzheimer's disease; single, pivotal Phase 2/3 adaptive design clinica
MIAMI, May 02, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report first quarter 2025 financial results and provide a business update on Thursday, May 8, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details: Conference Call Number: 1.877.407.0789 Conference ID: 13752361 Call meTM Feature: Click HereWebcast: Click Here An archived replay of the webcast will be available o
Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more than 90% enrollment and is expected to complete enrollment in the second quarter of 2025Lomecel-B™ Biological License Application (BLA) submission for full traditional approval anticipated in 2026, if ELPIS II is successfulFDA meeting anticipated late in first quarter of 2025 to discuss possible development paths for Lomecel-B™ in mild Alzheimer's diseaseWHO International Nonproprietary Names (INN) Expert Committee approved "laromestrocel" for the non-proprietary name of Lomecel-B™Total Revenue
MIAMI, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report full-year 2024 financial results and provide a business update on Friday, February 28, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details: Conference Call Number:1.877.407.0789Conference ID:13751432 Call meTM Feature:Click HereWebcast:Click Here An archived replay of the webcast will be available on
MIAMI, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report third quarter 2024 financial results and provide a business update on Tuesday, November 12, 2024 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call Details: Conference Call Number:1.877.407.0789Conference ID:13749428 Call me™ Feature:Click HereWebcast:Click Here An archived replay of the webcast will be available on the "Events & Presentations" se
MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report second quarter 2024 financial results and provide a business update on Wednesday, August 14, 2024 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call Details: Conference Call Number:1.877.407.0789Conference ID:13747923Call me™ Feature:Click HereWebcast:Click Here An archived replay of the webcast will be available on the "Events & Presentations" sec
Phase 2b clinical trial evaluating Lomecel-BTM in rare pediatric disease HLHS on track for completing enrollment by end of 2024Data from Phase 2a clinical trial evaluating Lomecel-BTM in Alzheimer's Disease selected for Featured Research Oral Presentation at 2024 Alzheimer's Association International ConferenceCompleted two financings in April raising gross proceeds of $11.4 million to fund continued clinical developmentFocused expenditure management reduced first quarter Total Operating Expenses 8% year-over-yearCompany to host conference call and webcast today at 5:00pm ET MIAMI, May 14, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medi
MIAMI, May 02, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will report first quarter 2024 financial results and provide a business update on Tuesday, May 14, 2024 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 5:00 p.m. ET. Conference Call Details: Conference Call Number: 1.877.407.0789 Conference ID: 13745868 Call meTM Feature: Click Here Webcast: Click Here An archived replay of the webcast will be available on the "Events & Presentations" section of the Company's website following the co
Company Announces 2024 Strategic Priorities Focused on Advancement of Lomecel-B™ in Hypoplastic Left Heart Syndrome ELPIS II Phase 2 Trial of Lomecel-B™ in HLHS Continues Enrollment; Completion of Study Enrollment Anticipated in 2024 Long-term Survival Data from ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association Announced Additional Validating Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer's Disease Gross Proceeds of $6.4 Million in Equity Financing Secured in Q4 Registered Direct Offerings Company to Hold Conference Call and Webcast Today, February 27, 2023